Clinical Trial

CAR T-cell Therapy in Patients With Renal Dysfunction

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-06-09; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2024-12-11
Trial Details
NCT Number NCT05909059
Lead Sponsor Northside Hospital, Inc.
Collaborators: Blood and Marrow Transplant Group of Georgia
Conditions Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
Enrollment 20 participants
Start Date 2024-11-18
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20